Clinical Trials Browser

Phase 2 × Lymphoma, Mantle-Cell × polatuzumab vedotin × Clear all

NCT04659044 2024-09-19

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Terminated

3 enrolled 11 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05868395 2024-05-29

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT04913103 2021-06-04

CLSGMCLPOLA

Phase 2 Not yet recruiting

Lymphoma, Mantle-Cell